ReviewJournal of neuro-oncology2015
Chemotherapy-induced peripheral neuropathies in hematological malignancies.
Review in Journal of neuro-oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 54 citations in OpenAlex.
- Treatment emergent peripheral neuropathy in the CASSIOPEIA trial.Haematologica · 2022Trial
- Prevalence and factors associated with chemotherapy induced peripheral neuropathy among adult patients with cancer at Mbarara Regional Cancer Centre: a cross-sectional study.BMC neurology · 2026Article
- Review
- Cured but not well - haematological cancer survivors' experiences of chemotherapy-induced peripheral neuropathy in everyday life: a phenomenological-hermeneutic study.Journal of cancer survivorship : research and practice · 2025Article
- Herb-drug interactions in oncology: pharmacodynamic/pharmacokinetic mechanisms and risk prediction.Chinese medicine · 2025Review
- Distinct Trajectories of Chemotherapy-Induced Peripheral Neuropathy in Lymphoma Survivors Treated With R-CHOP.Oncology nursing forum · 2025Article
- Serendipity in Neuro-Oncology: The Evolution of Chemotherapeutic Agents.International journal of molecular sciences · 2025Review
- The course of chemotherapy-induced peripheral neuropathy (CIPN) in hematological patients treated with vincristine, bortezomib, or lenalidomide: the NOVIT study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Observational
- Parthenolide: pioneering new frontiers in hematological malignancies.Frontiers in pharmacology · 2025Review
- DNA damage caused by chemotherapy has duality, and traditional Chinese medicine may be a better choice to reduce its toxicity.Frontiers in pharmacology · 2024Review
- Animal models of chemotherapy-induced peripheral neuropathy for hematological malignancies: A review.Ibrain · 2023Review
- Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review.British journal of haematology · 2022Review
- Refractory postherpetic neuralgia in a multiple myeloma patient with lenalidomide maintenance therapy: a case report.The Journal of international medical research · 2022Article
- A mechanistic understanding of the relationship between skin innervation and chemotherapy-induced neuropathic pain.Frontiers in pain research (Lausanne, Switzerland) · 2022Review
- Validation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity Questionnaire for the Latin American Population.International journal of breast cancer · 2022Article
- Prevention of chemotherapy-induced peripheral neuropathy: A review of recent findings.Critical reviews in oncology/hematology · 2020Review
- Mechanisms of Chemotherapy-Induced Peripheral Neuropathy.International journal of molecular sciences · 2019Review
- Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced Toxicities.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Review
- Peripheral neuropathy in children and adolescents treated for cancer.The Lancet. Child & adolescent health · 2018Review
- Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies.Current hematologic malignancy reports · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent developments in the treatment of hematological malignancies, especially with the advent of proteasome inhibitors and immunomodulatory drugs in plasma cell dyscrasias, call for an increased collaboration between hematologists and neurologists. This collaboration involves differentiating chemotherapy-induced peripheral neuropathies (CiPN) from disease-related neurologic complications, early recognition of CiPN and treatment of neuropathic pain. Multiple myeloma, Waldenstrom's macroglobulinemia and light-chain amyloidosis frequently present with peripheral neuropathy. In addition, multiple myeloma, non-Hodgkin lymphomas and leukemia's may mimic peripheral neuropathy by compression or invasion of the extra/intradural space. Platinum compounds, vinca alkaloids, proteasome inhibitors and immunomodulatory drugs may all cause CiPN, each with different and often specific clinical characteristics. Early recognition, by identifying the distinct clinical phenotype of CiPN, is of crucial importance to prevent irreversible neurological damage. No recommendations can be given on the use of neuroprotective strategies because of a lack of convincing clinical evidence. Finally, CiPN caused by vinca-alkaloids, proteasome inhibitors and immunomodulatory drugs is often painful and neurologists are best equipped to treat this kind of painful neuropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.